A Phase 2/3 interventional study of Avanz Phleum pratense and Placebo in Allergic Rhinoconjunctivitis, sponsored by ALK-Abelló A/S. Completed at 1 site in Germany. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2014-01-22.
Sponsored by ALK-Abelló A/S · Phase 2/3, Interventional, and Treatment
The purpose of the trial is to evaluate the efficacy of two dosing schedules of Avanz SQ+ (Standardised Quality) Phleum pratense compared to placebo in subjects with grass pollen induced allergic rhinoconjunctivitis with or without asthma.
ALK-Abelló A/S is the lead sponsor of 66 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Avanz Phleum pratense
Drug: Avanz Phleum pratense
Drug: Placebo
Suspension for Injection, Every 6 weeks for one year
Suspension for Injection, Every 6 weeks for one year
Recording of rhinoconjunctivitis symptoms
Time frame: Daily recordings during the grass pollen season 2012
Recording of symptomatic allergy medication use
Time frame: Daily recordings during the grass pollen seasons 2012
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ALK-Abelló A/S